Cover Image
Market Research Report

Respiratory Syncytial Virus Vaccines

Published by Datamonitor Healthcare Product code 858205
Published Content info 209 Pages
Delivery time: 1-2 business days
Price
Back to Top
Respiratory Syncytial Virus Vaccines
Published: October 5, 2018 Content info: 209 Pages
Description

OVERVIEW

Respiratory syncytial virus (RSV) is an enveloped, non-segmented, single-stranded, negative-sense RNA virus belonging to the Paramyxoviridae family. RSV is the leading cause of bronchiolitis in infants, and is estimated to be responsible for 22% of all episodes of acute lower respiratory tract infections in young children. Almost all children are infected with RSV within the first two years of life, and approximately 0.5-2.0% of infections will result in hospitalization. RSV is also recognized as a major cause of morbidity in immunosuppressed adults and the elderly.

MARKET SNAPSHOT

  • Pipeline vaccines will drive rapid growth of the RSV prophylaxis market to $3.1bn in the 2025/26 season.
  • Synagis sales will remain flat until 2020/21, after which they could be threatened by infant and maternal vaccines.
  • Pipeline vaccine candidates could render the use of monoclonal antibodies obsolete by the 2025/26 season.
Table of Contents
Product Code: DMKC12379

TABLE OF CONTENTS

FORECAST: RESPIRATORY SYNCYTIAL VIRUS VACCINES (Published on 05 October 2018)

  • OVERVIEW
  • RECENT FORECAST UPDATES
  • MARKET DEFINITION AND METHODOLOGY
  • FORECAST AND FUTURE TRENDS
  • US MARKET FORECAST
  • FRANCE MARKET FORECAST
  • GERMANY MARKET FORECAST
  • ITALY MARKET FORECAST
  • SPAIN MARKET FORECAST
  • UK MARKET FORECAST

MARKETED DRUGS: RESPIRATORY SYNCYTIAL VIRUS (Published on 05 October 2018)

  • OVERVIEW
  • PRODUCT PROFILE: SYNAGIS

PIPELINE: RESPIRATORY SYNCYTIAL VIRUS (Published on 05 October 2018)

  • OVERVIEW
  • CLINICAL PIPELINE OVERVIEW
  • ADDITIONAL PHARMA INTELLIGENCE PIPELINE RESOURCES
  • PRODUCT PROFILE (EARLY STAGE): AD26.RSV.PREF
  • PRODUCT PROFILE (EARLY STAGE): CHAD155-RSV
  • PRODUCT PROFILE (EARLY STAGE): GSK-3003891A
  • PRODUCT PROFILE (EARLY STAGE): LIVE-ATTENUATED RSV VACCINES
  • PRODUCT PROFILE (EARLY STAGE): MEDI8897
  • PRODUCT PROFILE (EARLY STAGE): MVA-BN RSV
  • PRODUCT PROFILE (EARLY STAGE): RSV PREF VACCINE
  • PRODUCT PROFILE (LATE STAGE): RSV F VACCINE

LIST OF FIGURES

  • Figure 1: Patient-based forecasting methodology for RSV vaccines
  • Figure 2: Price sources and calculations, by country
  • Figure 3: RSV prophylaxis total market value in the US and five major EU markets, by country, 2016/17-2025/26
  • Figure 4: RSV prophylaxis total market value in the US and five major EU markets, by class, 2016/17-2025/26
  • Figure 5: Synagis sales across the five major EU markets, by country, 2016/17-2025/26
  • Figure 6: RSV vaccines sales in the US and five major EU markets, by risk group, 2016/17-2025/26
  • Figure 7: Elderly RSV vaccine sales in the US and five major EU markets, by country, 2016/17-2025/26
  • Figure 8: Maternal RSV vaccine sales in the US and five major EU markets, by country, 2016/17-2025/26
  • Figure 9: Synagis sales in the US, by risk group, 2016/17-2025/26
  • Figure 10: Total US RSV prophylaxis sales, by class, 2016/17-2025/26
  • Figure 11: RSV vaccines sales in the US, by risk group, 2016/17-2025/26
  • Figure 12: Synagis sales in France, by risk group, 2016/17-2025/26
  • Figure 13: Total France RSV prophylaxis sales, by class, 2016/17-2025/26
  • Figure 14: RSV vaccines sales in France, by risk group, 2016/17-2025/26
  • Figure 15: Synagis sales in Germany, by risk group, 2016/17-2025/26
  • Figure 16: Total Germany RSV prophylaxis sales, by class, 2016/17-2025/26
  • Figure 17: RSV vaccines sales in Germany, by risk group, 2016/17-2025/26
  • Figure 18: Synagis sales in Italy, by risk group, 2016/17-2025/26
  • Figure 19: Total Italy RSV prophylaxis sales, by class, 2016/17-2025/26
  • Figure 20: RSV vaccines sales in Italy, by risk group, 2016/17-2025/26
  • Figure 21: Synagis sales in Spain, by risk group, 2016/17-2025/26
  • Figure 22: Total Spain RSV prophylaxis sales, by class, 2016/17-2025/26
  • Figure 23: RSV vaccines sales in Spain, by risk group, 2016/17-2025/26
  • Figure 24: Synagis sales in the UK, by risk group, 2016/17-2025/26
  • Figure 25: Total UK RSV prophylaxis sales, by class, 2016/17-2025/26
  • Figure 26: RSV vaccines sales in the UK, by risk group, 2016/17-2025/26
  • Figure 27: Synagis for respiratory syncytial virus - SWOT analysis
  • Figure 28: Synagis sales for RSV across the US and five major EU markets, 2016/17-2025/26
  • Figure 29: Ad26.RSV.preF RSV for RSV prophylaxis - SWOT analysis
  • Figure 30: Potential sales for RSV vaccines across the US and five major EU markets, by risk group, 2016/17-2025/26
  • Figure 31: ChAd155-RSV for RSV prophylaxis - SWOT analysis
  • Figure 32: Potential sales for RSV vaccines in infants across the US and five major EU markets, by country, 2016/17-2025/26
  • Figure 33: GSK-3003891A for RSV prophylaxis - SWOT analysis
  • Figure 34: Potential sales for RSV vaccines for pregnant women across the US and five major EU markets, by country, 2016/17-2025/26
  • Figure 35: Live-attenuated RSV vaccines franchise for RSV prophylaxis - SWOT analysis
  • Figure 36: Potential sales for RSV vaccines in infants across the US and five major EU markets, by country, 2016/17-2025/26
  • Figure 37: MEDI8897 for RSV prophylaxis - SWOT analysis
  • Figure 38: MVA-BN RSV for RSV prophylaxis - SWOT analysis
  • Figure 39: Potential sales for RSV vaccines in the elderly across the US and five major EU markets, by country, 2016/17-2025/26
  • Figure 40: RSV preF vaccine for RSV prophylaxis - SWOT analysis
  • Figure 41: Potential sales for RSV vaccines in the elderly across the US and five major EU markets, by country, 2016/17-2025/26
  • Figure 42: RSV F vaccine for RSV prophylaxis - SWOT analysis
  • Figure 43: Potential sales for RSV vaccines across the US and five major EU markets, by risk group, 2016/17-2025/26

LIST OF TABLES

  • Table 1: Number of immunized patients across the US and five major EU markets, by country (000s), 2016/17-2025/26
  • Table 2: Comparison of AAP Synagis prophylaxis guidelines in the 2013/14 season and in the 2014/15 season
  • Table 3: US RSV vaccines market forecast, 2016/17-2025/26
  • Table 4: Immunization coverage rates in the US, by risk group (%), 2016/17-2025/26
  • Table 5: France RSV vaccines market forecast, 2016/17-2025/26
  • Table 6: Immunization coverage rates in France, by risk group (%), 2016/17-2025/26
  • Table 7: Germany RSV vaccines market forecast, 2016/17-2025/26
  • Table 8: Immunization coverage rates in Germany, by risk group (%), 2015/16-2024/25
  • Table 9: Italy RSV vaccines market forecast, 2016/17-2025/26
  • Table 10: Immunization coverage rates in Italy, by risk group (%), 2016/17-2025/26
  • Table 11: Spain RSV vaccines market forecast, 2016/17-2025/26
  • Table 12: Immunization coverage rates in Spain, by risk group (%), 2016/17-2025/26
  • Table 13: UK RSV vaccines market forecast, 2016/17-2025/26
  • Table 14: Immunization coverage rates in the UK, by risk group (%), 2016/17-2025/26
  • Table 15: Synagis drug profile
  • Table 16: Synagis Phase III data in RSV
  • Table 17: Recommendations for palivizumab immunization by national authorities, 2018
  • Table 18: Synagis sales for RSV across the US and five major EU markets, by country ($m), 2016/17-2025/26
  • Table 19: Profiled pipeline products in development for RSV prophylaxis
  • Table 20: Ad26.RSV.preF drug profile
  • Table 21: Ad26.RSV.preF ongoing Phase I/II clinical trials in RSV vaccination
  • Table 22: Potential sales for RSV vaccines across the US and five major EU markets, by risk group ($m), 2016/17-2025/26
  • Table 23: ChAd155-RSV drug profile
  • Table 24: ChAd155-RSV completed clinical trial in RSV vaccination
  • Table 25: ChAd155-RSV ongoing clinical trial in RSV vaccination
  • Table 26: Potential sales for RSV vaccines in infants across the US and five major EU markets, by country ($m), 2016/17-2025/26
  • Table 27: GSK-3003891A drug profile
  • Table 28: GSK-3003891A completed Phase II clinical trials in RSV vaccination
  • Table 29: GSK-3003891A completed Phase II clinical trial in RSV vaccination
  • Table 30: Potential sales for RSV vaccines for pregnant women across the US and five major EU markets, by country ($m), 2016/17-2025/26
  • Table 31: RSV cps2 drug profile
  • Table 32: RSV delta NS2/delta 1313/I1314L drug profile
  • Table 33: RSV MEDI delta M2-2 backbone drug profile
  • Table 34: Summary of completed Phase I trials of RSV cps2, RSV D46/NS2/N/delta M2-2-HindIII, and RSV MEDI delta M2-2 for RSV infection
  • Table 35: Summary of ongoing Phase I trial of RSV delta NS2/delta 1313/I1314L and RSV MEDI delta M2-2 for RSV infection
  • Table 36: Potential sales for RSV vaccines in infants across the US and five major EU markets, by country ($m), 2016/17-2025/26
  • Table 37: MEDI8897 drug profile
  • Table 38: MEDI8897 Phase II clinical trial in RSV prophylaxis
  • Table 39: MEDI8897 Phase I trial data in RSV prophylaxis
  • Table 40: MVA-BN RSV drug profile
  • Table 41: MVA-BN RSV completed Phase I and Phase II clinical trials in RSV vaccination
  • Table 42: Potential sales for RSV vaccines in the elderly across the US and five major EU markets, by country ($m), 2016/17-2025/26
  • Table 43: RSV preF vaccine drug profile
  • Table 44: RSV preF vaccine Phase I/II trial data in RSV prophylaxis
  • Table 45: Potential sales for RSV vaccines in the elderly across the US and five major EU markets, by country ($m), 2016/17-2025/26
  • Table 46: RSV F vaccine profile
  • Table 47: RSV F vaccine Phase III Resolve data for RSV vaccination
  • Table 48: RSV F vaccine ongoing clinical trial in RSV vaccination
  • Table 49: RSV F vaccine key Phase II data in RSV vaccination
  • Table 50: Potential sales for RSV vaccines across the US and five major EU markets, by risk group ($m), 2016/17-2025/26
Back to Top